# Submitting an Abstract for STATGEN2024


> Presentation title:

Assessing the Evidence for a Causal Effect of Fibromuscular Dysplasia on
Chronic Kidney and Biomarkers of Kidney Function: A Mendelian
Randomization Study

> Abstract (max 1200 characters):

Fibromuscular dysplasia (FMD) is a noninflammatory and
nonatherosclerotic disease of artery walls that often affects
medium-sized artery beds, including those of the renal arteries (Olin
and Sealove 2011; Mousa and Gill 2013; Sang et al. 1989). Multiple
studies and case reports have implicated renal artery FMD in impaired
kidney function (Hunt et al. 1965; Oliva-Damaso et al. 2018;
Mounier-Vehier et al. 2002; Twist, Leeuw, and Kroon 2018). We sought to
quantify the causal effects of: FMD on chronic kidney disease, FMD on
plasma Cystatin C level, and FMD on plasma creatinine level. We used
publicly available summary statistics in a two-sample Mendelian
randomization study. Specifically, we used genetic instruments for FMD
from a meta-analysis of six genome-wide association studies of
multifocal FMD (Georges et al. 2021). For each putative outcome
variable, we performed a two-sample Mendelian randomization analysis
with inverse-variance weighted, weighted median, and MR-Egger methods.
We obtained association effect estimates for putative outcomes from
publicly available summary statistics from UK Biobank GWAS (“UK Biobank
GWAS” 2018).

## References

<div id="refs" class="references csl-bib-body hanging-indent"
entry-spacing="0">

<div id="ref-georges2021genetic" class="csl-entry">

Georges, Adrien, Min-Lee Yang, Takiy-Eddine Berrandou, Mark K Bakker,
Ozan Dikilitas, Soto Romuald Kiando, Lijiang Ma, et al. 2021. “Genetic
Investigation of Fibromuscular Dysplasia Identifies Risk Loci and Shared
Genetics with Common Cardiovascular Diseases.” *Nature Communications*
12 (1): 6031.

</div>

<div id="ref-hunt1965hypertension" class="csl-entry">

Hunt, James C, Edgar G Harrison Jr, Sheldon G Sheps, Philip E Bernatz,
George D Davis, Arthur H Bulbulian, and MAYO CLINIC AND MAYO FOUNDATION.
1965. “Hypertension Caused by Fibromuscular Dysplasia of the Renal
Arteries.” *Postgraduate Medicine* 38 (1): 53–63.

</div>

<div id="ref-mounier2002parenchymal" class="csl-entry">

Mounier-Vehier, Claire, Christophe Lions, Olivier Jaboureck, Patrick
Devos, Stephan Haulon, Maud Wibaux, Alain Carré, and Jean-Paul Beregi.
2002. “Parenchymal Consequences of Fibromuscular Dysplasia Renal Artery
Stenosis.” *American Journal of Kidney Diseases* 40 (6): 1138–45.

</div>

<div id="ref-mousa2013renal" class="csl-entry">

Mousa, Albeir Y, and Gurpreet Gill. 2013. “Renal Fibromuscular
Dysplasia.” In *Seminars in Vascular Surgery*, 26:213–18. 4. Elsevier.

</div>

<div id="ref-olin2011diagnosis" class="csl-entry">

Olin, Jeffrey W, and Brett A Sealove. 2011. “Diagnosis, Management, and
Future Developments of Fibromuscular Dysplasia.” *Journal of Vascular
Surgery* 53 (3): 826–36.

</div>

<div id="ref-oliva2018kidneys" class="csl-entry">

Oliva-Damaso, Nestor, Jorge Costa-Fernandez, Elena Oliva-Damaso, Rafael
Bravo-Marques, Francisca Lopez, Maria Del Mar Castilla, Julia Sequeira,
and Juan Payan. 2018. “Kidneys Are Key in Secondary Hypertension: A Case
of Fibromuscular Dysplasia.” *The Lancet* 392 (10161): 2298.

</div>

<div id="ref-sang1989etiologic" class="csl-entry">

Sang, Christine N, Paul K Whelton, Ulrike M Hamper, Margaret Connolly,
Saadoon Kadir, Robert I White, Roger Sanders, Kung-Yee Liang, and Wilma
Bias. 1989. “Etiologic Factors in Renovascular Fibromuscular Dysplasia.
A Case-Control Study.” *Hypertension* 14 (5): 472–79.

</div>

<div id="ref-van2018renal" class="csl-entry">

Twist, Daan JL van, Peter W de Leeuw, and Abraham A Kroon. 2018. “Renal
Artery Fibromuscular Dysplasia and Its Effect on the Kidney.”
*Hypertension Research* 41 (9): 639–48.

</div>

<div id="ref-neale_lab_gwas" class="csl-entry">

“UK Biobank GWAS.” 2018. <http://www.nealelab.is/uk-biobank/>.

</div>

</div>
